Find Ipragliflozin manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

VMF

NDC API

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

US Medicaid

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 761423-87-4, Suglat, Asp-1941, Asp1941, Ipragliflozin [inn], (2s,3r,4r,5s,6r)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
Molecular Formula
C21H21FO5S
Molecular Weight
404.5  g/mol
InChI Key
AHFWIQIYAXSLBA-RQXATKFSSA-N
FDA UNII
3N2N8OOR7X

Ipragliflozin
Ipragliflozin is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2.
1 2D Structure

Ipragliflozin

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
2.1.2 InChI
InChI=1S/C21H21FO5S/c22-15-6-5-12(21-20(26)19(25)18(24)16(10-23)27-21)7-13(15)9-14-8-11-3-1-2-4-17(11)28-14/h1-8,16,18-21,23-26H,9-10H2/t16-,18-,19+,20-,21+/m1/s1
2.1.3 InChI Key
AHFWIQIYAXSLBA-RQXATKFSSA-N
2.1.4 Canonical SMILES
C1=CC=C2C(=C1)C=C(S2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)F
2.1.5 Isomeric SMILES
C1=CC=C2C(=C1)C=C(S2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)F
2.2 Other Identifiers
2.2.1 UNII
3N2N8OOR7X
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (1s)-1,5-anhydro-1-(3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl)-d-glucitol

2. Asp-1941

3. Asp1941

4. Suglat

2.3.2 Depositor-Supplied Synonyms

1. 761423-87-4

2. Suglat

3. Asp-1941

4. Asp1941

5. Ipragliflozin [inn]

6. (2s,3r,4r,5s,6r)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

7. Ipragliflozin (asp1941)

8. 3n2n8oor7x

9. Chembl2018096

10. (1s)-1,5-anhydro-1-c-[3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl]-d-glucitol

11. Ipragliflozin (inn)

12. (1s)-1,5-anhydro-1-c-(3-((1-benzothiophen-2-yl)methyl)-4-fluorophenyl)-d-glucitol

13. Asp 1941

14. Unii-3n2n8oor7x

15. Ipragliflozin-l-proline

16. Ipragliflozin [mi]

17. (2s,3r,4r,5s,6r)-2-(3-(benzo[b]thiophen-2-ylmethyl)-4-fluorophenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol

18. Schembl337645

19. Ipragliflozin [who-dd]

20. Gtpl9394

21. Chebi:134724

22. Dtxsid701032738

23. Amy38779

24. Ex-a2770

25. Bdbm50381554

26. Mfcd19443744

27. S8637

28. Zinc38897728

29. Akos025405258

30. Ccg-268693

31. Db11698

32. Ncgc00378606-02

33. Ac-29008

34. As-39358

35. Hy-14894

36. D10196

37. Q17193526

38. (1s)-1,5-anhydro-1-(3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl)-d-glucitol

39. (1s)-1,5-anhydro-1-[3-(1-benzothien-2-ylmethyl)-4-fluorophenyl]-d-glucitol

40. (1s)-1,5-anhydro-1-c-[3-(1-benzothiophene-2-ylmethyl)-4-fluorophenyl]-d-glucitol

41. D-glucitol,1,5-anhydro-1-c-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-, (1s)-

42. (2s,3r,4r,5s,6r)-2-{3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl}-6-(hydroxymethyl)oxane-3,4,5-triol

43. D-glucitol, 1,5-anhydro-1-c-(3-(benzo(b)thien-2-ylmethyl)-4-fluorophenyl)-, (1s)-

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 404.5 g/mol
Molecular Formula C21H21FO5S
XLogP32.5
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count7
Rotatable Bond Count4
Exact Mass404.10937310 g/mol
Monoisotopic Mass404.10937310 g/mol
Topological Polar Surface Area118 Ų
Heavy Atom Count28
Formal Charge0
Complexity525
Isotope Atom Count0
Defined Atom Stereocenter Count5
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Sodium-Glucose Transporter 2 Inhibitors

Compounds that inhibit SODIUM-GLUCOSE TRANSPORTER 2. They lower blood sugar by preventing the reabsorption of glucose by the kidney and are used in the treatment of TYPE 2 DIABETES MELLITUS. (See all compounds classified as Sodium-Glucose Transporter 2 Inhibitors.)


4.2 ATC Code

A - Alimentary tract and metabolism

A10 - Drugs used in diabetes

A10B - Blood glucose lowering drugs, excl. insulins

A10BK - Sodium-glucose co-transporter 2 (sglt2) inhibitors

A10BK05 - Ipragliflozin


API SUPPLIERS

read-more
read-more

01

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Metrochem

02

Honour Lab Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHonour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Company Banner

03

Shamrock Pharmachemi

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTogether we can improve the quality of life

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Company Banner

04

Maithri Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMaithri Drugs: Dedicated to your API needs.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF BR arrow-down AUDIT
Company Banner

05

Fuxin Long Rui Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BOS Manchester
Not Confirmed
arrow

Fuxin Long Rui Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BOS Manchester
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

06

Smilax Laboratories Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BOS Manchester
Not Confirmed
arrow

Smilax Laboratories Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BOS Manchester
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

07

Juzen Chemical Corporation

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BOS Manchester
Not Confirmed
arrow

Juzen Chemical Corporation

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BOS Manchester
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF arrow-down VMF Others AUDIT
blank

08

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BOS Manchester
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BOS Manchester
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

09

Kukjeon Pharmaceutical

South Korea

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BOS Manchester
Not Confirmed
arrow

Kukjeon Pharmaceutical

South Korea

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BOS Manchester
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

Korea Biochem Pharm

South Korea

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BOS Manchester
Not Confirmed
arrow

Korea Biochem Pharm

South Korea

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BOS Manchester
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF arrow-down VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

Ipragliflozin

About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Metrochem

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHonour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.

Flag India
Digital Content Digital Content

Ipragliflozin

About the Company : Honour is a leading global CDMO and a trusted manufacturer of specialty chemicals and ingredients. With seven world-class facilities built to meet global safety and quality standar...

Honour is a leading global CDMO and a trusted manufacturer of specialty chemicals and ingredients. With seven world-class facilities built to meet global safety and quality standards, we are committed to delivering excellence with innovative, holistic solutions to clients across the globe by leveraging our expertise in chemistry. Operating through our two core verticals - Honour Synthesis and Honour Specialty, we embrace the science of partnership and possibilities. Our team of over 2,500 professionals collaborates closely with pharmaceutical, biotechnology, and specialty industries worldwide to develop practical, scalable solutions.
Company Banner

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTogether we can improve the quality of life

Flag India
Digital Content Digital Content

Ipragliflozin

About the Company : Shamrock Pharmachemi Pvt Ltd. is a globally recognized API leader with over 26 years of expertise in human and veterinary pharmaceuticals. Operating in 40+ countries, we own two st...

Shamrock Pharmachemi Pvt Ltd. is a globally recognized API leader with over 26 years of expertise in human and veterinary pharmaceuticals. Operating in 40+ countries, we own two state-of-the-art manufacturing facilities in Gujarat and collaborate with 16+ exclusive partner plants. Proudly holding the title of 'Largest Exporter for 12 Molecules Worldwide', we maintain the highest quality standards including USFDA, EU-GMP, WHO-GMP, and other stringent international certifications. Our robust regulatory compliance (DMF, CEP, ICH Q7) and customer-focused approach make us the preferred 'API Partner in India' for pharmaceutical companies worldwide
Company Banner

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMaithri Drugs: Dedicated to your API needs.

Flag India
Digital Content Digital Content

Ipragliflozin-L-Proline

About the Company : Maithri Drugs Pvt. Ltd. is a trusted global partner in Active Pharmaceutical Ingredients (APIs), supplying to pharmaceutical leaders in 60+ countries. With APIs spanning antivirals...

Maithri Drugs Pvt. Ltd. is a trusted global partner in Active Pharmaceutical Ingredients (APIs), supplying to pharmaceutical leaders in 60+ countries. With APIs spanning antivirals, antibiotics, ARVs, CNS, and cardiovascular segments, we deliver innovation with reliability. Our facilities are approved by US FDA, EDQM, Health Canada, and WHO-GMP, backed by numerous global DMFs and recognition as an Ecovadis-rated company. Supported by strong R&D, global patents, and customer-centric practices, Maithri ensures world-class APIs with regulatory excellence and exceptional service.
Company Banner

05

CPhI India
Not Confirmed
arrow
arrow
CPhI India
Not Confirmed

Ipragliflozin

About the Company : Kukjeon Pharmaceutical has been contributing towards advancing Korea’s pharmaceutical industry with its active pharmaceutical ingredients (API) based on professional capacity bui...

Kukjeon Pharmaceutical has been contributing towards advancing Korea’s pharmaceutical industry with its active pharmaceutical ingredients (API) based on professional capacity built up over the course of 50 years. Currently, we supply API to over 200 pharmaceutical and electronics companies at home and abroad. We are a chemical total solution provider that offers a whole range of chemical-based products and services, equipped with an organizational system and capacity to conduct research and development as well as foundational businesses.
blank

06

CPhI India
Not Confirmed
arrow
arrow
CPhI India
Not Confirmed

Ipragliflozin

About the Company : Smilax Laboratories Limited is a research-driven, vertically integrated pharmaceutical company manufacturing Active Pharmaceutical Ingredients, API Intermediates and NDDS/Pellets f...

Smilax Laboratories Limited is a research-driven, vertically integrated pharmaceutical company manufacturing Active Pharmaceutical Ingredients, API Intermediates and NDDS/Pellets for the generics market across the world. Set up in 2005, Smilax has emerged a reliable supplier of generic products in the global market today. Set up in 2005, Smilax has emerged a reliable supplier of generic products in the global market today.Set up in 2005, Smilax has emerged a reliable supplier of generic products in the global market today. Smilax manufactures APIs and API Intermediates at its state-of-the-art manufacturing facilities located at Hyderabad, Telangana and Visakhapatnam, Andhra Pradesh, India. Supported by a highly qualified and competent technical team, and endowed with strengths in research and development, Smilax continues to expand its presence in the world of pharmaceuticals.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Metformin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.


Lead Product(s): Metformin,Ipragliflozin

Therapeutic Area: Endocrinology Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 18, 2017

blank

01

CPhI India
Not Confirmed
CPhI India
Not Confirmed

Details : Metformin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 18, 2017

blank
  • Development Update

Details:

Ipragliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.


Lead Product(s): Ipragliflozin,Inapplicable

Therapeutic Area: Endocrinology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Astellas Pharma

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 09, 2017

blank

02

Seoul National University Bundang Hospital

Country
arrow
CPhI India
Not Confirmed

Seoul National University Bundang Hospital

Country
arrow
CPhI India
Not Confirmed

Details : Ipragliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 09, 2017

blank

Details:

Ipragliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 1.


Lead Product(s): Ipragliflozin,Insulin

Therapeutic Area: Endocrinology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 13, 2016

blank

03

CPhI India
Not Confirmed
CPhI India
Not Confirmed

Details : Ipragliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 1.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 13, 2016

blank

Details:

Ipragliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.


Lead Product(s): Ipragliflozin,Insulin

Therapeutic Area: Endocrinology Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 28, 2016

blank

04

CPhI India
Not Confirmed
CPhI India
Not Confirmed

Details : Ipragliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 28, 2016

blank
  • Development Update

Details:

Ipragliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.


Lead Product(s): Ipragliflozin,Inapplicable

Therapeutic Area: Endocrinology Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Miscellaneous

Sponsor: Severance Hospital | Samsung Medical Center | Kyung Hee University Hospital at Gangdong | Astellas Pharma

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 06, 2016

blank

05

Asan Medical Center

Country
arrow
CPhI India
Not Confirmed

Asan Medical Center

Country
arrow
CPhI India
Not Confirmed

Lead Product(s) : Ipragliflozin,Inapplicable

Therapeutic Area : Endocrinology

Highest Development Status : Phase IV

Partner/Sponsor/Collaborator : Severance Hospital | Samsung Medical Center | Kyung Hee University Hospital at Gangdong | Astellas Pharma

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Ipragliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 06, 2016

blank

Details:

Sitagliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.


Lead Product(s): Sitagliptin Phosphate,Ipragliflozin

Therapeutic Area: Endocrinology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 15, 2015

blank

06

Merck & Co

U.S.A
arrow
CPhI India
Not Confirmed

Merck & Co

U.S.A
arrow
CPhI India
Not Confirmed

Details : Sitagliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 15, 2015

blank

Details:

Ipragliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.


Lead Product(s): Ipragliflozin,Sitagliptin Phosphate

Therapeutic Area: Endocrinology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 15, 2015

blank

07

Merck & Co

U.S.A
arrow
CPhI India
Not Confirmed

Merck & Co

U.S.A
arrow
CPhI India
Not Confirmed

Details : Ipragliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 15, 2015

blank

Details:

Ipragliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.


Lead Product(s): Ipragliflozin,Sitagliptin Phosphate

Therapeutic Area: Endocrinology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 30, 2015

blank

08

Merck & Co

U.S.A
arrow
CPhI India
Not Confirmed

Merck & Co

U.S.A
arrow
CPhI India
Not Confirmed

Details : Ipragliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 30, 2015

blank

Details:

ASP1941 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.


Lead Product(s): Ipragliflozin,Inapplicable

Therapeutic Area: Endocrinology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 20, 2015

blank

09

CPhI India
Not Confirmed
CPhI India
Not Confirmed

Details : ASP1941 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

August 20, 2015

blank

Details:

ASP1941 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.


Lead Product(s): Ipragliflozin,Inapplicable

Therapeutic Area: Endocrinology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 22, 2015

blank

10

CPhI India
Not Confirmed
CPhI India
Not Confirmed

Details : ASP1941 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 22, 2015

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATE SUPPLIERS

read-more
read-more

01

CPhI India
Not Confirmed
arrow
CPhI India
Not Confirmed
arrow

CAS Number : 1034305-17-3

End Use API : Ipragliflozin

About The Company : Beijing Cooperate Pharmaceutical Co.,Ltd is a high-tech company specializing in pharmaceutical and advanced material, involving API,pharmaceutical intermediates...

blank

02

CPhI India
Not Confirmed
arrow
CPhI India
Not Confirmed
arrow

CAS Number : 1034305-17-3

End Use API : Ipragliflozin

About The Company : Chemvisai Labs is a dynamic pharmaceutical partner established with a clear vision: to become a leading and trusted force in the industry. We address critical u...

blank

03

CPhI India
Not Confirmed
arrow
CPhI India
Not Confirmed
arrow

CAS Number : 86087-23-2

End Use API : Ipragliflozin

About The Company : Guangzhou Topwork Chemical Co., Ltd. Specializes in manufacturing corticosteroid and relative intermediates. We provide high quality products and excellent serv...

blank

04

CPhI India
Not Confirmed
arrow
CPhI India
Not Confirmed
arrow

CAS Number : 915095-94-2

End Use API : Ipragliflozin

About The Company : Nanjing Lift Pharmaceutical is a specialized company concentrating on the R&D, production, marketing and technical service of APIs, pharmaceutical intermediates...

blank

05

CPhI India
Not Confirmed
arrow
CPhI India
Not Confirmed
arrow

CAS Number : 86087-23-2

End Use API : Ipragliflozin

About The Company : Nanjing Lift Pharmaceutical is a specialized company concentrating on the R&D, production, marketing and technical service of APIs, pharmaceutical intermediates...

blank

06

CPhI India
Not Confirmed
arrow
CPhI India
Not Confirmed
arrow

CAS Number : -1034305-17-3

End Use API : Ipragliflozin

About The Company : Smilax Laboratories Limited is a research-driven, vertically integrated pharmaceutical company manufacturing Active Pharmaceutical Ingredients, API Intermediate...

blank

07

CPhI India
Not Confirmed
arrow
CPhI India
Not Confirmed
arrow

CAS Number : 32384-65-9

End Use API : Ipragliflozin

About The Company : We introduce ourselves as manufacturer of Active Pharmaceutical Ingredients (API) and intermediates with a professional approach that is aimed at finest results...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Looking for 761423-87-4 / Ipragliflozin API manufacturers, exporters & distributors?

Ipragliflozin manufacturers, exporters & distributors 1

62

PharmaCompass offers a list of Ipragliflozin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ipragliflozin manufacturer or Ipragliflozin supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ipragliflozin manufacturer or Ipragliflozin supplier.

PharmaCompass also assists you with knowing the Ipragliflozin API Price utilized in the formulation of products. Ipragliflozin API Price is not always fixed or binding as the Ipragliflozin Price is obtained through a variety of data sources. The Ipragliflozin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Ipragliflozin

Synonyms

761423-87-4, Suglat, Asp-1941, Asp1941, Ipragliflozin [inn], (2s,3r,4r,5s,6r)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

Cas Number

761423-87-4

Unique Ingredient Identifier (UNII)

3N2N8OOR7X

About Ipragliflozin

Ipragliflozin is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2.

Ipragliflozin-L-Proline Manufacturers

A Ipragliflozin-L-Proline manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ipragliflozin-L-Proline, including repackagers and relabelers. The FDA regulates Ipragliflozin-L-Proline manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ipragliflozin-L-Proline API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Ipragliflozin-L-Proline manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Ipragliflozin-L-Proline Suppliers

A Ipragliflozin-L-Proline supplier is an individual or a company that provides Ipragliflozin-L-Proline active pharmaceutical ingredient (API) or Ipragliflozin-L-Proline finished formulations upon request. The Ipragliflozin-L-Proline suppliers may include Ipragliflozin-L-Proline API manufacturers, exporters, distributors and traders.

click here to find a list of Ipragliflozin-L-Proline suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Ipragliflozin-L-Proline USDMF

A Ipragliflozin-L-Proline DMF (Drug Master File) is a document detailing the whole manufacturing process of Ipragliflozin-L-Proline active pharmaceutical ingredient (API) in detail. Different forms of Ipragliflozin-L-Proline DMFs exist exist since differing nations have different regulations, such as Ipragliflozin-L-Proline USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Ipragliflozin-L-Proline DMF submitted to regulatory agencies in the US is known as a USDMF. Ipragliflozin-L-Proline USDMF includes data on Ipragliflozin-L-Proline's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ipragliflozin-L-Proline USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Ipragliflozin-L-Proline suppliers with USDMF on PharmaCompass.

Ipragliflozin-L-Proline KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Ipragliflozin-L-Proline Drug Master File in Korea (Ipragliflozin-L-Proline KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Ipragliflozin-L-Proline. The MFDS reviews the Ipragliflozin-L-Proline KDMF as part of the drug registration process and uses the information provided in the Ipragliflozin-L-Proline KDMF to evaluate the safety and efficacy of the drug.

After submitting a Ipragliflozin-L-Proline KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Ipragliflozin-L-Proline API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Ipragliflozin-L-Proline suppliers with KDMF on PharmaCompass.

Ipragliflozin-L-Proline NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ipragliflozin-L-Proline as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Ipragliflozin-L-Proline API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Ipragliflozin-L-Proline as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Ipragliflozin-L-Proline and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ipragliflozin-L-Proline NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Ipragliflozin-L-Proline suppliers with NDC on PharmaCompass.

Ipragliflozin-L-Proline GMP

Ipragliflozin-L-Proline Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Ipragliflozin-L-Proline GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ipragliflozin-L-Proline GMP manufacturer or Ipragliflozin-L-Proline GMP API supplier for your needs.

Ipragliflozin-L-Proline CoA

A Ipragliflozin-L-Proline CoA (Certificate of Analysis) is a formal document that attests to Ipragliflozin-L-Proline's compliance with Ipragliflozin-L-Proline specifications and serves as a tool for batch-level quality control.

Ipragliflozin-L-Proline CoA mostly includes findings from lab analyses of a specific batch. For each Ipragliflozin-L-Proline CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Ipragliflozin-L-Proline may be tested according to a variety of international standards, such as European Pharmacopoeia (Ipragliflozin-L-Proline EP), Ipragliflozin-L-Proline JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ipragliflozin-L-Proline USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty